Uncategorised - European Medical Journal

Two Subtypes of Metastatic Prostate Cancer Identified

Scientists have identified two subtypes of metastatic prostate cancer that responding differently to treatment.

Physical Activity Shows Evidence of Cancer Prevention in the USA

Engaging in 5 hours per week of moderate-intensity exercise could prevent 46,000 cancer cases annually in the USA.

Patient-Reported Outcomes with Monoclonal Antibody Therapies in Patients with Moderate-to-Severe Plaque Psoriasis

Richard B. Warren highlighted Psoriasis Symptoms and Impacts Measure (P-SIM) responses from the Phase III BE VIVID trial in patients…

The Alternative: Music Therapy

Jonathan continues his series on alternative medicine by serenading us with the science of music therapy, exploring its use in pain management, stress relief, and overall health and wellbeing.

Assessing Disease Activity and Progression in Patients with Relapsing–Remitting Multiple Sclerosis: Interviews with Two Key Opinion Leaders

Multiple sclerosis is a common and chronic neurological disorder that affects over 2.8 million individuals worldwide every year…

The Emerging Role and Value of Homologous Recombination Deficiency Testing in Advanced Ovarian Cancer: Interviews with Four Key Opinion Leaders

Ovarian cancer is the seventh most common cancer in females,1-3 and the most lethal gynaecologic malignancy globally because of its vague…

Interview with Prof. Neil Johnson

Professor of Reproductive Health, Robinson Research Institute, Adelaide Gynecologist and REI Subspecialist, Auckland Gynecology Group and Repromed Auckland

Breast Cancer

From Diagnosis to Endocrine Management: Utilizing Genomic Profiling to Inform Comprehensive Treatment Planning for Women with Early-Stage Breast Cancer.

Presented by: Chair: Dr. Jonathan Sackier, Speakers: Dr. William Audeh, Dr. Alberto Montero

Efficacy and Safety of Monoclonal Antibody Therapies in Patients with Moderate-to-Severe Plaque Psoriasis

In the late-breaking research sessions, Reich presented BE RADIANT, the first Phase III trial to compare inhibition of IL-17A and IL-17F…

The Emerging Role and Value of HRD Testing in Ovarian Cancer

This episode is on the topic of ovarian cancer. Hear from two experts in the field, Professor Frederik Marmé and Professor Christina Fotopoulou, as they discuss the impact of late diagnosis and delayed treatment on patient outcomes, risk reduction strategies, and HRD testing.